Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierImmunityBio, Inc. (“ImmunityBio,” the “Company,” “we,” “us,” or “our”) is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Our approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients.
In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR
ImmunityBio, Inc. (IBRX) reported revenue of $51M in Q2 2026 (quarter ended Jun 30, 2026), up 94% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $230M. For the full year FY2025, revenue was $113M (+668% year on year) and net income −$351M.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.